A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin

Trial Profile

A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Peginterferon lambda-1a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms MAGNITUDE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Mar 2015 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
    • 30 Oct 2014 Planned End Date changed from 1 Aug 2015 to 1 Jan 2015 as reported by Clinicaltrials.gov.
    • 30 Oct 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2015 as reported by Clinicaltrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top